PLoS ONE (May 2010)

Patient retention and adherence to antiretrovirals in a large antiretroviral therapy program in Nigeria: a longitudinal analysis for risk factors.

  • Man Charurat,
  • Modupe Oyegunle,
  • Renata Benjamin,
  • Abdulrazaq Habib,
  • Emeka Eze,
  • Prince Ele,
  • Iquo Ibanga,
  • Samuel Ajayi,
  • Maria Eng,
  • Prosanta Mondal,
  • Usman Gebi,
  • Emilia Iwu,
  • Mary-Ann Etiebet,
  • Alash'le Abimiku,
  • Patrick Dakum,
  • John Farley,
  • William Blattner

DOI
https://doi.org/10.1371/journal.pone.0010584
Journal volume & issue
Vol. 5, no. 5
p. e10584

Abstract

Read online

Substantial resources and patient commitment are required to successfully scale-up antiretroviral therapy (ART) and provide appropriate HIV management in resource-limited settings. We used pharmacy refill records to evaluate risk factors for loss to follow-up (LTFU) and non-adherence to ART in a large treatment cohort in Nigeria.We reviewed clinic records of adult patients initiating ART between March 2005 and July 2006 at five health facilities. Patients were classified as LTFU if they did not return >60 days from their expected visit. Pharmacy refill rates were calculated and used to assess non-adherence. We identified risk factors associated with LTFU and non-adherence using Cox and Generalized Estimating Equation (GEE) regressions, respectively. Of 5,760 patients initiating ART, 26% were LTFU. Female gender (p 350 and 2 hours to the clinic (p = 0.03), had total ART duration of >6 months (p200 at ART initiation were at a higher risk of non-adherence. Patients who disclosed their HIV status to spouse/family (p = 0.01) and were treated with tenofovir-containing regimens (p < or = 0.001) were more likely to be adherent.These findings formed the basis for implementing multiple pre-treatment visit preparation that promote disclosure and active community outreaching to support retention and adherence. Expansion of treatment access points of care to communities to diminish travel time may have a positive impact on adherence.